استبيان جودة الحياة لالتهاب المفصل الروماتويدي
مراجع

1 2  de Jong، Z.؛ van der Heijde, D.؛ McKenna, S.P.؛ Whalley, D. (1997). "The reliability and construct validity of the RAQoL: a rheumatoid arthritis-specific quality of life instrument". Rheumatology. ج. 36 ع. 8: 878–883. DOI:10.1093/rheumatology/36.8.878. PMID:9291857. مؤرشف من الأصل في 2017-04-02. اطلع عليه بتاريخ 2013-09-30.
↑  Adams، Jo؛ Chapman, Judith؛ Bradley, Sarah؛ Ryan, Sarah Jane (2013). "Literacy levels required to complete routinely used patient-reported outcome measures in rheumatology". Rheumatology. ج. 52 ع. 3: 460–464. DOI:10.1093/rheumatology/kes296. PMID:23118412. مؤرشف من الأصل في 2017-04-01. اطلع عليه بتاريخ 2013-09-30.
1 2  Tijhuis، G.J.؛ de Jong, Z.؛ Zwinderman, A.H.؛ Zuijderduin, W.M.؛ Jansen, L.M.A.؛ Hazes, J.M.W.؛ Vliet Vlieland, T.P.M. (2001). "The validity of the Rheumatoid Arthritis Quality of Life (RAQoL) questionnaire". Rheumatology. ج. 40 ع. 10: 1112–1119. DOI:10.1093/rheumatology/40.10.1112. PMID:11600740. مؤرشف من الأصل في 2017-04-01. اطلع عليه بتاريخ 2013-09-30.
↑  Maska، L.؛ Anderson, J.؛ Michaud, K. (نوفمبر 2011). "Measures of functional status and quality of life in rheumatoid arthritis: Health Assessment Questionnaire Disability Index (HAQ), Modified Health Assessment Questionnaire (MHAQ), Multidimensional Health Assessment Questionnaire (MDHAQ), Health Assessment Questionnaire II (HAQ-II), Improved Health Assessment Questionnaire (Improved HAQ), and Rheumatoid Arthritis Quality of Life (RAQoL)". Arthritis Care & Research. ج. 63 ع. Supplement S11: S4–S13. DOI:10.1002/acr.20620. PMID:22588760.
↑  Whalley، D.؛ McKenna, S.P.؛ de Jong, Z.؛ van der Heijde, D. (1997). "Quality of life in rheumatoid arthritis". Rheumatology. ج. 36 ع. 8: 884–888. DOI:10.1093/rheumatology/36.8.884. PMID:9291858. مؤرشف من الأصل في 2017-04-01. اطلع عليه بتاريخ 2013-09-30.
↑  Marra، Carlo A.؛ Woolcott, John C.؛ Kopec, Jacek A.؛ Shojania, Kamran؛ Offer, Robert؛ Brazier, John E.؛ Esdaile, John M.؛ Anis, Aslam H. (أبريل 2005). "A comparison of generic, indirect utility measures (the HUI2, HUI3, SF-6D, and the EQ-5D) and disease-specific instruments (the RAQoL and the HAQ) in rheumatoid arthritis". Social Science & Medicine. ج. 60 ع. 7: 1571–1582. DOI:10.1016/j.socscimed.2004.08.034. PMID:15652688.
↑  Lillegraven، Siri؛ Kvien, Tore K. (أكتوبر 2007). "Measuring disability and quality of life in established rheumatoid arthritis". Best Practice & Research Clinical Rheumatology. ج. 21 ع. 5: 827–840. DOI:10.1016/j.berh.2007.05.004. PMID:17870030.
↑  "Measures Database". Galen-Research.com. Galen Research. مؤرشف من الأصل في 2023-03-14. اطلع عليه بتاريخ 2013-10-02.
↑  Eberhardt، Kerstin؛ Duckberg, Siv؛ Larsson, Britt-Marie؛ Johnson, Pia Malcus؛ Nived, Kerstin (يوليو 2009). "Measuring health related quality of life in patients with rheumatoid arthritis – reliability, validity, and responsiveness of a Swedish version of RAQoL". Scandinavian Journal of Rheumatology. ج. 31 ع. 1: 6–12. DOI:10.1080/030097402317255291. PMID:11922201. S2CID:42285569.
↑  Waimann، Christian A.؛ Dal Pra, Fernando M.؛ Marengo, Maria F.؛ Schneeberger, Emilce E.؛ Gagliardi, Susana؛ Maldonado Cocco, Jose A.؛ Sanchez, Monica؛ Garone, A.؛ Chaparro del Moral, Rafael E.؛ Rillo, Oscar L.؛ Salcedo, Mariana؛ Rosa, Javier E.؛ Ceballos, F.؛ Soriano, Enrique R.؛ Citera, Gustavo (يوليو 2012). "Quality of life of patients with rheumatoid arthritis in Argentina: reliability, validity, and sensitivity to change of a Spanish version of the Rheumatoid Arthritis Quality of Life questionnaire". Clinical Rheumatology. ج. 31 ع. 7: 1065–1071. DOI:10.1007/s10067-013-2397-x. PMID:24158632.
↑  Cox، S.R.؛ McWilliams, L.؛ Massy-Westropp, N.؛ Meads, D.M.؛ McKenna, S.P.؛ Proudman, S. (مايو 2007). "Adaptation of the RAQoL for use in Australia". Rheumatology International. ج. 27 ع. 7: 661–666. DOI:10.1007/s00296-006-0287-0. PMID:17195065. S2CID:28105906.
↑  Dougados، Maxime؛ Kissel, Karsten؛ Sheeran, Tom؛ Tak, Paul P.؛ Conaghan, Philip G.؛ Mola, Emilio Martin؛ Schett, Georg؛ Amital, Howard؛ Navarro-Sarabia, Federico؛ Hou, Antony؛ Bernasconi, Corrado؛ Huizinga, TWJ (2013). "Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY)". Annals of the Rheumatic Diseases. ج. 72 ع. 1: 43–50. DOI:10.1136/annrheumdis-2011-201282. PMC:3551223. PMID:22562983.
↑  Fahy، Sarah. "Efficacy of tocilizumab in patients with rheumatoid arthritis". Current Controlled Trials. DOI:10.1186/ISRCTN21216199. مؤرشف من الأصل في 2017-04-02. اطلع عليه بتاريخ 2013-10-02.{{استشهاد بدورية محكمة}}:  صيانة الاستشهاد: دوي مجاني غير معلم (link)
↑  Quinn، Mark A.؛ Conaghan, Philip G.؛ O'Connor, Philip J.؛ Karim, Zunaid؛ Greenstein, Adam؛ Brown, Andrew؛ Brown, Clare؛ Fraser, Alexander؛ Jarret, Stephen؛ Emery, Paul (يناير 2005). "Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: Results from a twelve-month randomized, double-blind, placebo-controlled trial". Arthritis & Rheumatism. ج. 52 ع. 1: 27–35. DOI:10.1002/art.20712. PMID:15641102.
↑  Bejarano، Victoria؛ Conaghan, Philip G.؛ Quinn, Mark A.؛ Saleem, Benazir؛ Emery, Paul (2010). "Benefits 8 years after a remission induction regime with an infliximab and methotrexate combination in early rheumatoid arthritis". Rheumatology. ج. 49 ع. 10: 1971–1974. DOI:10.1093/rheumatology/keq194. PMID:20595536. مؤرشف من الأصل في 2017-04-01. اطلع عليه بتاريخ 2013-10-02.
بوابة طب